Welcome to our dedicated page for Chimerix news (Ticker: CMRX), a resource for investors and traders seeking the latest updates and insights on Chimerix stock.
Chimerix, Inc. (NASDAQ: CMRX) is a pioneering biopharmaceutical company focused on the development of innovative antiviral therapeutics. Led by a team of experienced professionals, Chimerix aims to enhance the quality of life for patients across diverse medical fields, including transplant, oncology, acute care, and global health.
Chimerix leverages its proprietary lipid technology, resulting in two promising clinical-stage compounds: CMX001 and CMX157. These compounds have shown potential for improved activity, bioavailability, and safety over existing drugs. The lead compound, CMX001, is a broad-spectrum antiviral that combats double-stranded DNA (dsDNA) viruses, such as cytomegalovirus (CMV), adenovirus, BK virus, herpes simplex virus, and variola (smallpox). CMX001 has completed Phase 2 development for CMV prophylaxis and is currently in Phase 2 trials for adenovirus treatment in hematopoietic stem cell transplant (HSCT) recipients.
Chimerix’s portfolio also includes ONC201, an oral, first-in-class small molecule imipridone targeting H3 K27M-mutant gliomas. The Phase 3 ACTION trial for ONC201 is a major focus, enrolling patients at over 130 sites in 13 countries. This study aims to report interim overall survival data by early 2025. Additionally, Chimerix's second-generation compound, ONC206, is undergoing Phase I dose escalation trials, demonstrating anti-cancer activity in both CNS and non-CNS tumors.
Financially, Chimerix maintains a robust balance sheet with significant capital to fund ongoing operations, reflecting sound fiscal management. The company reported a net loss of $18.6 million for Q2 2023 but continues to advance its research and development initiatives.
Chimerix’s mission is to develop medications that significantly improve and extend the lives of patients battling severe diseases. With ongoing clinical trials, strategic financial planning, and a dedicated team, Chimerix is poised to make substantial contributions to global health.
Chimerix (NASDAQ:CMRX) announced a contract worth up to $25.3 million from the Public Health Agency of Canada for the procurement of TEMBEXA (brincidofovir). This agreement underscores the significance of TEMBEXA as a medical countermeasure. The delivery is expected to take place before Chimerix's pending transaction with Emergent BioSolutions. TEMBEXA is approved for smallpox and Chimerix will earn revenues before closing the Emergent deal and a 15%-20% royalty on future sales. The transaction's completion requires several conditions, including regulatory approvals.
Chimerix (NASDAQ:CMRX) announced a $9.3 million agreement to procure TEMBEXA® (brincidofovir) internationally, bolstering its role as a medical countermeasure. This contract aims to meet strategic stockpile needs and fulfill obligations linked to a potential BARDA contract. Chimerix's revenue from TEMBEXA before the pending transaction with Emergent BioSolutions will remain with the company, while post-transaction, it will earn royalties of 15% on international and 20% on U.S. sales exceeding 1.7 million treatment courses. Closing of the deal is contingent upon several conditions.
Chimerix (NASDAQ:CMRX) announced that CEO Mike Sherman will present a corporate overview at the Jefferies Healthcare Conference on June 8, 2022, at 3:30 p.m. in New York City. The presentation will highlight Chimerix's mission to develop medicines to improve and extend the lives of patients with serious diseases. A live audio webcast of the presentation will be accessible on the Investor Relations section of Chimerix’s website and archived for 90 days.
Chimerix's leading clinical program, ONC201, targets H3 K27M-mutant glioma.
DURHAM, N.C., May 17, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX) announced that CEO Mike Sherman will present a pre-recorded corporate update at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 7:00 a.m. ET. An audio webcast of the presentation will be accessible on Chimerix's Investor Relations webpage and archived for approximately 90 days. Chimerix focuses on developing medicines to improve the lives of patients with serious diseases, with its leading program being ONC201 for H3 K27M-mutant glioma.
Chimerix (CMRX) has secured up to $337.5 million from Emergent BioSolutions through the sale of worldwide rights to TEMBEXA, with an upfront payment of $225 million. The company is shifting focus to the development of ONC201 for H3 K27M-mutant glioma, planning a Phase 3 study by year-end 2022. The DSTAT program has been terminated to streamline efforts. Financially, Chimerix reported a net loss of $24.8 million for Q1 2022, a decrease from a $97.4 million loss in Q1 2021, while revenues dropped to $15,000 from $1.4 million a year earlier.
Chimerix (NASDAQ:CMRX) announced a definitive agreement with Emergent BioSolutions to acquire exclusive rights to brincidofovir, including TEMBEXA, for $225 million plus potential milestone payments of up to $100 million. The deal enhances Chimerix's balance sheet, allowing focus on its development pipeline while maintaining participation in TEMBEXA's economics through royalties and milestone payments. Closing conditions include a procurement contract with BARDA. TEMBEXA, approved by the FDA for smallpox, represents a strategic asset in biodefense.
Chimerix (NASDAQ:CMRX) announced that Josh Allen, Ph.D., its Chief Technology Officer of Imipridones, will participate in a panel discussion titled “Exploring New Targets for Pediatric Brain Cancer.” This event is hosted by Maxim Group and is scheduled for May 19, 2022, at 9:00 a.m. ET. An audio webcast of the event will be accessible on Chimerix's Investor Relations website for approximately 90 days. Chimerix is dedicated to developing medicines that enhance and prolong patients' lives. Notably, the FDA approved its drug TEMBEXA for smallpox treatment in June 2021.
Chimerix (NASDAQ:CMRX) will host a live conference call on May 16, 2022, at 8:30 a.m. ET to discuss its Q1 2022 financial results and provide a business overview. The call can be accessed via phone or through a webcast on the company's website. Chimerix focuses on developing medicines for serious diseases and has received FDA approval for TEMBEXA for smallpox. Additionally, the company is advancing its clinical programs for ONC201 and dociparstat sodium (DSTAT) in oncology.
Chimerix (NASDAQ:CMRX) announced that CEO Mike Sherman will present a pre-recorded talk at the Maxim Group 2022 Virtual Growth Conference from March 28-30, 2022. An audio webcast of the presentation will be accessible on Chimerix's Investor Relations website and archived for 90 days. Chimerix focuses on developing medicines for severe diseases, having received FDA approval for TEMBEXA to treat smallpox. The company's advanced clinical programs include ONC201 for glioma and dociparstat sodium (DSTAT) for acute myeloid leukemia.
Chimerix (NASDAQ:CMRX) announced its Q4 and full-year 2021 financial results, reporting a net loss of $39.5 million for Q4 and $173.2 million for the year. Revenue dropped to $46,000 in Q4 compared to $1.1 million in 2020, driven by the end of a BARDA contract. Notably, Chimerix achieved FDA approval for TEMBEXA as a smallpox treatment and reported promising data for ONC201 in glioma therapy. The company has submitted a BARDA RFP response regarding TEMBEXA and accepted preclinical data of CMX521 for a presentation at an antiviral conference.
FAQ
What is the current stock price of Chimerix (CMRX)?
What is the market cap of Chimerix (CMRX)?
What does Chimerix, Inc. do?
What are Chimerix's leading compounds?
What stages are Chimerix's clinical trials in?
How is Chimerix financially positioned?
What is the significance of the ONC201 Phase 3 ACTION trial?
What kind of partnerships does Chimerix have?
Where is Chimerix based?
How does Chimerix generate revenue?
What is unique about Chimerix’s lipid technology?
What is Chimerix's mission?
